The partnership has enabled Viralgen to scale up and complete a GMP trial material batch of Trogenix's therapy.

GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

“Unfortunately, this means we’ve made the difficult decision to cease vector manufacturing in Libertyville, a site that has operated at the highest level for BMS Cell Therapy,” she adde ...

AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to ...

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and ...